Elasmogen is led by industry professionals with broad experience that covers both big Pharma and early-stage biotech. The team has a demonstrated track-record of delivering biologic drugs to the clinic and of securing company exits via trade-sale and IPO.
Dr Caroline Barelle
With postgraduate qualifications in both business and science, Caroline has a strong commercial, bio-partnering and biologics drug discovery/development background. She has successfully led teams at Wyeth Inc and subsequently Pfizer Inc in Global Bio-therapeutic Technologies progressing early platform technologies to late stage clinical development. Prior to this she was Alliance and Programs Manager at Haptogen Ltd and a key part of the acquisition team that successfully exited the business to Wyeth Inc. She is a member of the Enterprise, Skills and Strategy Board (ESSB), the Opportunity North East Board (ONE), the RS Entrepreneur in Residence for Queen’s University Belfast and sits on the Royal Society Science, Industry and Translation Committee.
She has been awarded a prestigious Royal Society of Edinburgh commercialisation Fellowship and is a doctoral graduate from the University of Aberdeen in Biochemistry and has an MBA from Robert Gordon University.
Professor Andy Porter FRSB, FRSE
Chief Technical Officer
Andy was one of the founders of Elasmogen and as CTO manages the company’s extensive patent portfolio and IP strategy. He also holds a number of Non-Exec positions in Life Science and other businesses in Scotland. Andy is part-time Professor of Medical Biotechnology and Director of the Scottish Biologics Facility, University of Aberdeen. Since 2005 he has been a Fellow of the Royal Society of Edinburgh and until recently was VP Business. Andy has worked with academics and companies across the world, developing biologics to a range of diagnostic and therapeutic targets including: oncology, inflammation, CNS disease and most recently Covid-19. Andy is a graduate of St Andrews University.